Skip to main content
SpringerLink
Log in

Natural History, Role of Biopsy, and Active Surveillance of Renal Masses

  • Chapter
  • First Online:
Renal Cancer

  • 663 Accesses

Abstract

With increased utilization of cross-sectional imaging over the past few decades, we have observed a rise in asymptomatic, clinically localized, small renal masses (SRMs). Despite increased detection and treatment, mortality rates from kidney cancer remain relatively unchanged. This suggests that a proportion of small renal masses are indolent tumors that may not require surgical intervention. From these observations, active surveillance (AS) has emerged as an alternative management strategy in appropriately selected patients. Furthermore, the use of AS has provided the basis for describing the natural history of renal masses managed without intervention. As data from prospective registries continue to mature, we have observed that many incidental renal masses demonstrate slow growth kinetics with a low rate of progression to metastatic disease. Therefore, the use of AS appears to be a safe initial management option in patients with SRMs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  Google Scholar 

  2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. Jama. 1999;281(17):1628–31.

    Article  CAS  PubMed  Google Scholar 

  3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.

    Article  PubMed  Google Scholar 

  4. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78–83.

    Article  PubMed  Google Scholar 

  5. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008;179(6):2131–5.

    Article  PubMed  Google Scholar 

  6. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.

    Article  CAS  PubMed  Google Scholar 

  7. Russo P, Uzzo RG, Lowrance, W, Asnis-Alibozek, A, LaFrance, N, Libertino, JA, Pryma, DA, Divgi, CR, editors. Incidence of Benign Versus Malignant Renal Tumors in Selected Studies. Genitourinary Cancers Symposium, Orlando Fl, USA; 2012.

    Google Scholar 

  8. Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.

    Article  PubMed  Google Scholar 

  9. Remzi M, Ozsoy M, Klingler HC, Susani M, Waldert M, Seitz C, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176(3):896–9.

    Article  PubMed  Google Scholar 

  10. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.

    Article  PubMed  Google Scholar 

  11. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.

    Article  PubMed  Google Scholar 

  12. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.

    Article  PubMed  Google Scholar 

  13. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28(2):311–7.

    Google Scholar 

  14. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–8.

    Article  CAS  PubMed  Google Scholar 

  15. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. Jama. 1998;280(11):975–80.

    Article  CAS  PubMed  Google Scholar 

  16. Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650–9.

    Article  PubMed  Google Scholar 

  17. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.

    Article  PubMed  Google Scholar 

  18. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7.

    Article  PubMed  Google Scholar 

  19. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197(3):589–97.

    Article  CAS  PubMed  Google Scholar 

  20. Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995;2(2):71–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3):863–6.

    Article  PubMed  Google Scholar 

  22. Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8(9):473–7.

    Article  CAS  PubMed  Google Scholar 

  23. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007;110(5):1010–4.

    Article  PubMed  Google Scholar 

  24. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8; discussion 8–9.

    Article  PubMed  Google Scholar 

  25. Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–27.

    Article  PubMed  Google Scholar 

  26. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–52.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fernando HS, Duvuru S, Hawkyard SJ. Conservative management of renal masses in the elderly: our experience. Int Urol Nephrol. 2007;39(1):203–7.

    Article  PubMed  Google Scholar 

  28. Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007;177(2):466–70; discussion 70.

    Article  PubMed  Google Scholar 

  29. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy–natural history, complications, and outcome. Urology. 2004;64(5):909–13.

    Article  PubMed  Google Scholar 

  30. Matsuzaki M, Kawano Y, Morikawa H, Shiga Y, Murata H, Komatsu H. Conservative management of small renal tumors. Hinyokika Kiyo. 2007;53(4):207–11.

    PubMed  Google Scholar 

  31. Rosales JC, Haramis G, Moreno J, Badani K, Benson MC, McKiernan J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010;183(5):1698–702.

    Article  PubMed  Google Scholar 

  32. Siu W, Hafez KS, Johnston WK 3rd, Wolf JS Jr. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 2007;25(2):115–9.

    Article  PubMed  Google Scholar 

  33. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004;11(5):2407–10.

    PubMed  Google Scholar 

  34. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738–45.

    Article  PubMed  Google Scholar 

  35. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64(1):49–52.

    Article  PubMed  Google Scholar 

  36. Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J. 2007;1(2):120–2.

    PubMed  PubMed Central  Google Scholar 

  37. McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, et al. Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and >5-yr clinical outcomes. Eur Urol. 2018;74(2):157–64.

    Article  PubMed  Google Scholar 

  38. Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, et al. Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry. J Urol. 2017;199(3):641–8.

    Article  PubMed  Google Scholar 

  39. Organ M, Jewett M, Basiuk J, Morash C, Pautler S, Siemens DR, et al. Growth kinetics of small renal masses: a prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Can Urol Assoc J. 2014;8(1–2):24–7.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997–1006.

    Article  PubMed  Google Scholar 

  41. Pierorazio PM, Patel HD, Johnson MH, Sozio SM, Sharma R, Iyoha E, et al. Distinguishing malignant and benign renal masses with composite models and nomograms: a systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy. Cancer. 2016;122(21):3267–76.

    Article  PubMed  Google Scholar 

  42. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.

    Article  PubMed  Google Scholar 

  43. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):20of metastatic event33–6.

    Google Scholar 

  44. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–20.

    Article  PubMed  Google Scholar 

  45. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33; discussion 4.

    Article  PubMed  Google Scholar 

  46. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7. discussion 7.

    Article  PubMed  Google Scholar 

  47. Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182(1):41–5.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kunkle DA, Crispen PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007;177(5):1692–6; discussion 7.

    Article  PubMed  Google Scholar 

  49. Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features–preliminary experience. Radiology. 2012;262(3):884–93.

    Article  PubMed  Google Scholar 

  50. Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63–5.

    Article  PubMed  Google Scholar 

  51. Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, et al. Prospective evaluation of (99 m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69(3):413–6.

    Article  PubMed  Google Scholar 

  52. Uzzo RG. Renal masses–to treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol. 2008;180(2):433–4.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9.

    Article  PubMed  Google Scholar 

  54. Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.

    Article  PubMed  Google Scholar 

  55. Crispen PL, Blute ML. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009;55(2):307–9.

    Article  PubMed  Google Scholar 

  56. Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC. Renal mass biopsy: always, sometimes, or never? Eur Urol. 2016;70(3):403–6.

    Article  PubMed  Google Scholar 

  57. Richard PO, Jewett MA, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, et al. Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol. 2015;68(6):1007–13.

    Article  PubMed  Google Scholar 

  58. Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178(2):379–86.

    Article  PubMed  Google Scholar 

  59. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy–a renaissance? J Urol. 2008;179(1):20–7.

    Article  PubMed  Google Scholar 

  60. Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73(3):586–90; discussion 90–1.

    Article  PubMed  Google Scholar 

  61. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171(5):1802–5.

    Article  PubMed  Google Scholar 

  62. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf JS Jr, Wood DP Jr. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188(2):563–70.

    Article  PubMed  Google Scholar 

  63. Lechevallier E, Andre M, Barriol D, Daniel L, Eghazarian C, De Fromont M, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology. 2000;216(2):506–10.

    Article  CAS  PubMed  Google Scholar 

  64. Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84.

    Article  PubMed  Google Scholar 

  65. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5; quiz 295.

    Article  CAS  PubMed  Google Scholar 

  66. Leveridge M, Shiff D, Chung H, Legere L, Fernandes K, Evans A, et al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J Urol. 2010;183(4):e321.

    Google Scholar 

  67. Blumenfeld AJ, Guru K, Fuchs GJ, Kim HL. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology. 2010;76(3):610–3.

    Article  PubMed  Google Scholar 

  68. Khan AA, Shergill IS, Quereshi S, Arya M, Vandal MT, Gujral SS. Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists. BMC Urol. 2007;7:10.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wood BJ, Khan MA, McGovern F, Harisinghani M, Hahn PF, Mueller PR. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161(5):1470–4.

    Article  CAS  PubMed  Google Scholar 

  70. Richard PO, Lavallee LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, et al. Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? J Urol. 2018;200(4):731–6.

    Article  PubMed  Google Scholar 

  71. Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35(4):627–34; vii.

    Article  PubMed  Google Scholar 

  72. Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008;72(1):138–42.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Review. Radiology. 1991;178(1):253–8.

    Article  CAS  PubMed  Google Scholar 

  74. Abe M, Saitoh M. Selective renal tumour biopsy under ultrasonic guidance. Br J Urol. 1992;70(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  75. Auvert J, Abbou CC, Lavarenne V. Needle tract seeding following puncture of renal oncocytoma. Prog Clin Biol Res. 1982;100:597–8.

    CAS  PubMed  Google Scholar 

  76. Gibbons RP, Bush WH Jr, Burnett LL. Needle tract seeding following aspiration of renal cell carcinoma. J Urol. 1977;118(5):865–7.

    Article  CAS  PubMed  Google Scholar 

  77. Kiser GC, Totonchy M, Barry JM. Needle tract seeding after percutaneous renal adenocarcinoma aspiration. J Urol. 1986;136(6):1292–3.

    Article  CAS  PubMed  Google Scholar 

  78. Shenoy PD, Lakhkar BN, Ghosh MK, Patil UD. Cutaneous seeding of renal carcinoma by Chiba needle aspiration biopsy. Case report. Acta Radiol. 1991;32(1):50–2.

    Article  CAS  PubMed  Google Scholar 

  79. Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: tumor dissemination by renal needle aspiration. J Urol. 1986;136(2):446–8.

    Article  CAS  PubMed  Google Scholar 

  80. Giorgadze T, Qureshi F, Aulicino M, Jacques SM. Retroperitoneal recurrence of a stage 1 renal cell carcinoma four years following core biopsy and fine needle aspiration: possible needle tract seeding. Diagn Cytopathol. 2012;41(5):474.

    Article  PubMed  Google Scholar 

  81. Jilani G, Mohamed D, Wadia H, Ramzi K, Meriem J, Houssem L, et al. Cutaneous metastasis of renal cell carcinoma through percutaneous fine needle aspiration biopsy: case report. Dermatol Online J. 2010;16(2):10.

    PubMed  Google Scholar 

  82. Smith AD, Remer EM, Cox KL, Lieber ML, Allen BC, Shah SN, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology. 2012;262(1):152–60.

    Article  PubMed  Google Scholar 

  83. Richter F, Kasabian NG, Irwin RJ Jr, Watson RA, Lang EK. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. Urology. 2000;55(3):348–52.

    Article  CAS  PubMed  Google Scholar 

  84. Truong LD, Todd TD, Dhurandhar B, Ramzy I. Fine-needle aspiration of renal masses in adults: analysis of results and diagnostic problems in 108 cases. Diagn Cytopathol. 1999;20(6):339–49.

    Article  CAS  PubMed  Google Scholar 

  85. Visapaa H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61(4):845–50.

    Article  PubMed  Google Scholar 

  86. Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer. 1995;75(11):2714–9.

    Article  CAS  PubMed  Google Scholar 

  87. Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur Urol. 1997;31(1):73–80.

    Article  CAS  PubMed  Google Scholar 

  88. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173(3):725–8.

    Article  CAS  PubMed  Google Scholar 

  89. Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56(3):510–5.

    Article  CAS  PubMed  Google Scholar 

  90. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35(1):133–7.

    Article  CAS  PubMed  Google Scholar 

  91. Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008;98(5):941–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999;84(3):268–72.

    Article  CAS  PubMed  Google Scholar 

  93. Sabo E, Miselevich I, Bejar J, Segenreich M, Wald M, Moskovitz B, et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol. 1997;80(6):864–8.

    Article  CAS  PubMed  Google Scholar 

  94. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180(2):515–9.

    Article  CAS  PubMed  Google Scholar 

  95. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.

    CAS  PubMed  Google Scholar 

  96. Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Oda T, Takahashi A, Miyao N, Yanase M, Masumori N, Itoh N, et al. Cell proliferation, apoptosis, angiogenesis and growth rate of incidentally found renal cell carcinoma. Int J Urol. 2003;10(1):13–8.

    Article  PubMed  Google Scholar 

  98. Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging. 2006;6:S52–62.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat Rev. Urol. 2010;7(5):258–66.

    Article  PubMed  Google Scholar 

  100. Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96(4):540–6.

    Article  PubMed  Google Scholar 

  101. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31(12):788–9.

    Article  PubMed  Google Scholar 

  102. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(3):422–7.

    Article  PubMed  Google Scholar 

  103. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.

    Article  CAS  PubMed  Google Scholar 

  104. Uzzo RG, Russo P, Chen D, Larson S, Bahnson R, Libertino JA, et al. The multicenter phase III redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell Renal Cell Carcinoma (ccRCC) (late breaking abstract; AUA, San Francisco). 2010.

    Google Scholar 

  105. Schachter LR, Bach AM, Snyder ME, Kattan MW, Russo P. The impact of tumour location on the histological subtype of renal cortical tumours. BJU Int. 2006;98(1):63–6.

    Article  PubMed  Google Scholar 

  106. Venkatesh R, Weld K, Ames CD, Figenshau SR, Sundaram CP, Andriole GL, et al. Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology. 2006;67(6):1169–74; discussion 74.

    Article  PubMed  Google Scholar 

  107. Weizer AZ, Gilbert SM, Roberts WW, Hollenbeck BK, Wolf JS Jr. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urol. 2008;180(4):1273–8.

    Article  PubMed  Google Scholar 

  108. Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011;60(2):241–8.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;163(3):730–6.

    Article  CAS  PubMed  Google Scholar 

  110. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8.

    Article  PubMed  Google Scholar 

  111. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25; vii.

    Article  PubMed  Google Scholar 

  112. Kutikov A, Egleston BL, Smaldone MC, Canter D, Wong YN, Uzzo RG. Quantification of competing risks of death in patients with localized Renal Cell Carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities. J Urol. 2012;188(6):2077–83.

    Google Scholar 

  113. Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol. 2003;23(2):71–7.

    Article  CAS  PubMed  Google Scholar 

  114. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

    Article  CAS  Google Scholar 

  115. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177(3):849–53; discussion 53–4.

    Article  PubMed  Google Scholar 

  116. Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5):555–9.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067–71.

    CAS  PubMed  Google Scholar 

  118. Mues AC, Haramis G, Badani K, Gupta M, Benson MC, McKiernan JM, et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010;76(3):620–3.

    Article  PubMed  Google Scholar 

  119. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Nahon O, Coulange C. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology. 2005;66(6):1181–5.

    Article  PubMed  Google Scholar 

  120. Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MA. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J Urol. 2011;186(4):1218–22.

    Article  PubMed  Google Scholar 

  121. Jewett MA, Finelli A, Morash C, Chin JL, Siemens R, Tanguay S, et al. Active surveillance of small renal masses: a prospective multi-center Canadian Uro-Oncology Group Trial: Abstract No. 896. J Urol. 2009;181(4 supplement):320.

    Article  Google Scholar 

  122. Heilbrun ME, Yu J, Smith KJ, Dechet CB, Zagoria RJ, Roberts MS. The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol. 2012;187(1):39–43.

    Article  PubMed  Google Scholar 

  123. Chang SL, Cipriano LE, Harshman LC, Garber AM, Chung BI. Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol. 2011;185(5):1591–7.

    Article  PubMed  Google Scholar 

  124. Cooperberg MR, et al. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the national cancer database, 1993 to 2004. J Urol. 2008;179(6):2132.

    Article  Google Scholar 

  125. Ristau BT, et al. Active surveillance for small renal masses: when less is more. Eur Urol Focus. 2016;2(6):660–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery/Division of Urology, UConn Health, Farmington, CT, USA

    Benjamin T. Ristau

  2. Department of Urology, NYU Winthrop Hospital, Garden City, NY, USA

    Anthony Corcoran

  3. Department of Surgical Oncology, Division of Urology, Fox Chase Cancer Center – Temple University Health System, Philadelphia, PA, USA

    Marc C. Smaldone, Robert G. Uzzo & David Y. T. Chen

Authors
  1. Benjamin T. Ristau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Corcoran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc C. Smaldone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert G. Uzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Y. T. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Y. T. Chen .

Editor information

Editors and Affiliations

  1. Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    John A. Libertino

  2. Associate Professor of Urology, Tufts University School of Medicine, Boston, MA, USA

    Jason R. Gee

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ristau, B.T., Corcoran, A., Smaldone, M.C., Uzzo, R.G., Chen, D.Y.T. (2020). Natural History, Role of Biopsy, and Active Surveillance of Renal Masses. In: Libertino, J., Gee, J. (eds) Renal Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-24378-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-24378-4_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-24377-7

  • Online ISBN: 978-3-030-24378-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation